<cip>
<pubtype>IM__|__dis__|__|__|__Journal Article__|__Case Reports</pubtype>
<pgfirst>2</pgfirst>
<copyright>Elsevier B.V.</copyright>
<keywordids>hl0000066__|__hl0000068__|__hl0000070__|__hl0000072__|__hl0000074__|__hl0000076__|__hl0000078__|__hl0000080__|__hl0000082__|__hl0000084__|__hl0000086__|__hl0000088__|__hl0000090__|__hl0000092</keywordids>
<subtype>publication</subtype>
<aid>1914</aid>
<srctype>Article</srctype>
<coverdateend>2010-12-31</coverdateend>
<coverdatetext>01 May 2010</coverdatetext>
<ref>         </ref>
<sectionid>h000001__|__h000002</sectionid>
<copyrightyr>2010</copyrightyr>
<pubdatetxt>20100501</pubdatetxt>
<doi>10.1016/j.jcv.2010.01.006</doi>
<body>   Case presentation  A HIV positive 50-year-old male presented to hospital with a fever of 39 °C 8 days after commencing his sixth cycle of CHOP chemotherapy for stage IV B plasmablastic lymphoma.  The lymphoma was diagnosed 4 months earlier when he presented with anaemia, weight loss and a peri-anal mass. A HIV test was positive, CD4 count was 18 × 10 6  cells/L and HIV RNA 500,000 copies/mL. Antiretrovirals (tenofovir, emtricitabine, darunavir and ritonavir) and antimicrobial prophylaxis (acyclovir 400 mg BD, fluconazole 50 mg OD, azithromycin 1250 mg weekly and co-trimoxazole 960 mg OD) were initiated prior to commencing cytotoxic chemotherapy. During the first five cycles he had several episodes of neutropenic sepsis, without microbiological diagnosis, treated empirically as per local guidelines.  On this presentation he complained of diarrhoea and a dry cough but no other localising symptoms. Over the previous week he noted an enlarging skin lesion on his leg. Examination revealed a 10 mm × 7 mm dry eschar on the right thigh ( The prevalence and incidence of CMV disease in patients with CD4 cell count &amp;lt;50  × 10 6  cells/L, were 20–40% and 15–20/100 patient-years, respectively.  The impact of HAART on reducing the incidence of opportunistic infections including CMV has been dramatic. The incidence of CMV end-organ diseases among persons with AIDS has declined to approximately 25% of that seen prior to the advent of HAART.  However, CMV infection ranging from asymptomatic virus shedding to severe organ disease continues to occur particularly among HIV infected patients not receiving maximal benefit from HAART due to treatment non-adherence, drug failure and therapy intolerance. Serological testing for CMV IgG and IgM, CMV mRNA PCR and CMV culture are poor prognostic indicators for the occurrence of CMV disease. CMV pp65 antigenaemia is a marker that can be detected early enough to allow initiation of pre-emptive therapy as there is data to suggest a 4-month interval between detection of the pp65 antigen in blood and onset of disease. CMV DNA PCR is thought to have good prognostic value for the occurrence of disease and can be performed in profoundly neutropenic patients.    (2)  Alternatively, surveillance throughout treatment with chemotherapeutic agents and commencement of antiviral treatment when viraemia is detected (pre-emptive therapy) and before viral mediated tissue destruction and specific organ dysfunction become clinically evident. This approach offers the benefits of reduced toxicity through targeting patients at high risk for CMV disease. However, it relies heavily on the availability of rapid, sensitive and reliable surveillance tests for early detection of CMV viraemia with the aim of predicting subsequent disease in time to be influenced by antiviral therapy and before symptomatic CMV infection is apparent. Plasma CMV DNA quantification by PCR is a reproducible and standardized tool with good prognostic value for the occurrence of disease.       Discussion  Pre-emptive treatment with antiviral agents of patients with CMV viraemia should be widely adopted as an alternative to routine prophylaxis to prevent CMV disease in HIV infected patients receiving further immunosuppression in the form of cytotoxic chemotherapy. Additional trials are required to determine the outcome and drawbacks of pre-emptive therapy and prophylaxis to prevent symptomatic CMV infection in HIV patients receiving chemotherapy.    Competing interests  None declared.   </body>
<statustype>S300</statustype>
<exactitemtitle> Febrile neutropenia in a HIV positive individual post-chemotherapy </exactitemtitle>
<exactsrctitle>Journal of Clinical Virology</exactsrctitle>
<keywords>CMV__|__Cytomegalovirus__|__HAART__|__highly active antiretroviral therapy__|__CHOP__|__cyclophosphamide, doxorubicin, vincristine and prednisolone__|__EBV__|__Epstein Barr Virus__|__HSV__|__herpes simplex virus__|__VZV__|__varicella zoster virus__|__MAC__|__Mycobacterium avium intracellularae complex</keywords>
<allsmall> Febrile neutropenia in a HIV positive individual post-chemotherapy   CMV, Cytomegalovirus, HAART, highly active antiretroviral therapy, CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone, EBV, Epstein Barr Virus, HSV, herpes simplex virus, VZV, varicella zoster virus, MAC, Mycobacterium avium intracellularae complex</allsmall>
<allmed> Febrile neutropenia in a HIV positive individual post-chemotherapy  Ridha, E., Cookson, H., Devitt, E., Nelson, M.  CMV, Cytomegalovirus, HAART, highly active antiretroviral therapy, CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone, EBV, Epstein Barr Virus, HSV, herpes simplex virus, VZV, varicella zoster virus, MAC, Mycobacterium avium intracellularae complex</allmed>
<all> Febrile neutropenia in a HIV positive individual post-chemotherapy  Ridha, E., Cookson, H., Devitt, E., Nelson, M.  CMV, Cytomegalovirus, HAART, highly active antiretroviral therapy, CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone, EBV, Epstein Barr Virus, HSV, herpes simplex virus, VZV, varicella zoster virus, MAC, Mycobacterium avium intracellularae complex</all>
<piecid>999999</piecid>
<collecid>JL-1s20S1386653210X0004X-1s20S1386653210000156</collecid>
<pubyr>2010</pubyr>
<heading1> Febrile neutropenia in a HIV positive individual post-chemotherapy </heading1>
<pdfeid>13866532/S1386653210000156/main.pdf</pdfeid>
<abs/>
<coverdatestart>2010-05-01</coverdatestart>
<srctitle>Journal of Clinical Virology</srctitle>
<pg>2-5 </pg>
<auth>Ridha, E.__|__Cookson, H.__|__Devitt, E.__|__Nelson, M.</auth>
<issn>1386-6532</issn>
<hubeid>1-s2.0-S1386653210X0004X</hubeid>
<itemtitle> Febrile neutropenia in a HIV positive individual post-chemotherapy </itemtitle>
<sectiontitle>Journal of Clinical Virology__|__ Febrile neutropenia in a HIV positive individual post-chemotherapy </sectiontitle>
<dedication/>
<daterevisedtxt/>
<volissue>Volume 48, Issue 1</volissue>
<contenttype>JL</contenttype>
<type>TEXT</type>
<jid>JCV</jid>
<coverimage>13866532/S1386653210X0004X/cov200h.gif__|__13866532/S1386653210X0004X/cov150h.gif</coverimage>
<pubdate>1272686400000</pubdate>
<cid>271981</cid>
<pglast>5</pglast>
<subjmain>Infectious Disease</subjmain>
<chemabst/>
<hubsectitle>Virology Question and Answer Scheme (VIROQAS)</hubsectitle>
<issue>1</issue>
<eid>1-s2.0-S1386653210000156</eid>
<vol>48</vol>
<origdateloaded>1308659521000</origdateloaded>
<authfull>Ridha, E.__|__Cookson, H.__|__Devitt, E.__|__Nelson, M.</authfull>
<pii>S1386-6532(10)00015-6</pii>
<filename>/prod/els/data/xocs/journals/S1386653210X0004X/S1386653210000156.xml</filename>
<srctitleabbr>J</srctitleabbr>
<medlineitemtitle>Febrile neutropenia in a HIV positive individual post-chemotherapy.</medlineitemtitle><medlineissn>1873-5967</medlineissn><medlinesrctitleabbr>J. Clin. Virol.</medlinesrctitleabbr><medlinesrctitle>Medline</medlinesrctitle><medlinecontenttype>MD</medlinecontenttype><medlinecid>298367</medlinecid><medlineeid>2-s2.0-20171139</medlineeid><medlinedate>20100501</medlinedate><medlinevolissue>48</medlinevolissue><medlinepg>- 2-5</medlinepg><medlinesubtype>publication</medlinesubtype><medlinesrctype>Abstract</medlinesrctype><medlineauth>Ridha, E__|__Cookson, H__|__Devitt, E__|__Nelson, M</medlineauth><citationsubset>IM</citationsubset><datecreatedtxt>20100416</datecreatedtxt><uniqueid>9815671</uniqueid><mshmajsubject2>complications__|__drug therapy__|__virology</mshmajsubject2><datecompletedtxt>20100714</datecompletedtxt><medlineitemtitle>Febrile neutropenia in a HIV positive individual post-chemotherapy.</medlineitemtitle><medlineissn>1873-5967</medlineissn><medlinesrctitleabbr>J. Clin. Virol.</medlinesrctitleabbr><medlinesrctitle>Medline</medlinesrctitle><medlinecontenttype>MD</medlinecontenttype><medlinecid>298367</medlinecid><medlineeid>2-s2.0-20171139</medlineeid><medlinedate>20100501</medlinedate><medlinevolissue>48</medlinevolissue><medlinepg>- 2-5</medlinepg><medlinesubtype>publication</medlinesubtype><medlinesrctype>Abstract</medlinesrctype><medlineauth>Ridha, E__|__Cookson, H__|__Devitt, E__|__Nelson, M</medlineauth><medlineitemtitle>Febrile neutropenia in a HIV positive individual post-chemotherapy.</medlineitemtitle><medlineissn>1873-5967</medlineissn><medlinesrctitleabbr>J. Clin. Virol.</medlinesrctitleabbr><medlinesrctitle>Medline</medlinesrctitle><medlinecontenttype>MD</medlinecontenttype><medlinecid>298367</medlinecid><medlineeid>2-s2.0-20171139</medlineeid><medlinedate>20100501</medlinedate><medlinevolissue>48</medlinevolissue><medlinepg>- 2-5</medlinepg><medlinesubtype>publication</medlinesubtype><medlinesrctype>Abstract</medlinesrctype><medlineauth>Ridha, E__|__Cookson, H__|__Devitt, E__|__Nelson, M</medlineauth></cip>
